Advanced search
Publication Cover
Modern Rheumatology Volume 29, 2019 - Issue 2
Journal homepage
718
Views
31
CrossRef citations to date
0
Altmetric
Original Article

Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study

Tsuneyo MimoriDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Correspondence[email protected]
,
Masayoshi HarigaiDivision of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan;
,
Tatsuya AtsumiDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan;
,
Takao FujiiDepartment of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan;
,
Masataka KuwanaDepartment of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan;
,
Hiroaki MatsunoMatsuno Clinic for Rheumatic Diseases, Toyama, Japan;
,
Shigeki MomoharaHakkeikai Incorporated Medical Institution, Shizuoka, Japan; ;Department of Orthopaedic Surgery, Keio University, Tokyo, Japan;
,
Syuji TakeiGraduate School of Medical and Dental Sciences, Comprehensive Child Health and Development Medicine, Kagoshima University, Kagoshima, Japan;
,
Naoto TamuraDepartment of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan;
,
Yoshinari TakasakiJuntendo University Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan;
,
Kazuhiko YamamotoLaboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan;
,
Satoshi IkeuchiFrontier PMS Section, Neurology Medical Department, Medical HQs, Eisai Co., Ltd., Tokyo, Japan;
,
Satoru KushimotoPost-Marketing Surveillance Group, Data Science and Administration Department, Toyama Chemical Co., Ltd., Tokyo, Japan;
&
Takao KoikeSapporo Medical Center NTT EC, Hokkaido, Japan
 show all
Pages 314-323 | Received 02 Feb 2018, Accepted 29 Mar 2018, Published online: 27 Apr 2018

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Q Shao, S Wang, H Jiang & L Liu. (2021) Efficacy and safety of iguratimod on patients with primary Sjögren’s syndrome: a randomized, placebo-controlled clinical trial. Scandinavian Journal of Rheumatology 50:2, pages 143-152.
Read now
Naoki Ishiguro, Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2020) Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction: Post-hoc analysis of an all-case post-marketing surveillance study of iguratimod. Modern Rheumatology 30:4, pages 633-639.
Read now
Naoki Ishiguro, Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2020) Investigation of the predictors of the response to Iguratimod therapy: A post-hoc analysis of post-marketing surveillance study. Modern Rheumatology 30:4, pages 626-632.
Read now
Yuji Nozaki, Asuka Inoue, Koji Kinoshita, Masanori Funauchi & Itaru Matsumura. (2020) Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis. Modern Rheumatology 30:2, pages 249-258.
Read now

Articles from other publishers (27)

Yuyi Xu, Ming Zhao, Jinxue Cao, Ting Fang, Jian Zhang, Yanli Zhen, Fangling Wu, Xiaohui Yu, Yaming Liu, Ji Li & Dongkai Wang. (2023) Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis. Acta Pharmaceutica Sinica B 13:11, pages 4417-4441.
Crossref
Satoshi Nagata, Ryo Yamasaki, Ezgi Ozdemir Takase, Kotaro Iida, Mitsuru Watanabe, Katsuhisa Masaki, Marion Heleen Cathérine Wijering, Hiroo Yamaguchi, Jun-ichi Kira & Noriko Isobe. (2023) Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation. Biology 12:9, pages 1217.
Crossref
Taibiao Lyu, Hui Jiang, Liuting Zeng, Suying Liu, Chengmei He, Chaowen Luo, Lin Qiao, Yan Zhao & Hua Chen. (2023) Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling. Arthritis Research & Therapy 25:1.
Crossref
Qingran Yan, Bei Liu, Jieying Wang, Hanlin Yin, Qianqian Li & Liangjing Lu. (2023) Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer. Frontiers in Medicine 10.
Crossref
Yuji Nozaki, Motohiro Oribe, Daisuke Tomita, Tetsu Itami, Shinya Hayashi, Toshihisa Maeda, Koji Fukuda, Ryosuke Kuroda, Keiko Funahashi, Tsukasa Matsubara, Koji Kinoshita & Itaru Matsumura. (2023) Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching. Modern Rheumatology 33:3, pages 472-480.
Crossref
Dan Ouyang, Yuan Zhi Ma, Jie Zou, Yong Long Wang, Zheng Chen, Yu Ying Yang, Bin Zou, Xin Li & Jian Zhong Cao. (2022) Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 13.
Crossref
Liuting Zeng, Qi He, Kailin Yang, Wensa Hao, Ganpeng Yu & Hua Chen. (2022) A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren’s Syndrome. Frontiers in Immunology 13.
Crossref
Liuting Zeng, Ganpeng Yu, Kailin Yang, Wensa Hao & Hua Chen. (2022) The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial. Frontiers in Pharmacology 12.
Crossref
Chao-Jun Hu, Li Zhang, Shuang Zhou, Nan Jiang, Jiu-Liang Zhao, Qian Wang, Xin-Ping Tian & Xiao-Feng Zeng. (2021) Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs. Journal of Orthopaedic Surgery and Research 16:1.
Crossref
Tao Zhang, Chao Ma, Zhiqiang Zhang, Huiyuan Zhang & Hongbo Hu. (2021) NF‐κB signaling in inflammation and cancer. MedComm 2:4, pages 618-653.
Crossref
Jingya Tan, Jiaqiang Dan & Yi Liu. (2021) Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum. BioMed Research International 2021, pages 1-7.
Crossref
Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2021) Effectiveness of drug safety measures for reducing the incidence of adverse drug reactions: Post-hoc analysis of data from all-case surveillance of iguratimod using generalized estimating equations. PLOS ONE 16:7, pages e0253513.
Crossref
Yan Li, Kunpeng Li, Zheng Zhao, Yanyan Wang, Jingyu Jin, Junhua Guo, Jie Zhang, Jianglin Zhang, Jian Zhu & Feng Huang. (2021) Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis. Frontiers in Medicine 8.
Crossref
Yuji Nozaki. (2021) Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World. Life 11:5, pages 457.
Crossref
Masao Tanaka. (2021) Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise. The Lancet Regional Health - Western Pacific 10, pages 100144.
Crossref
Rong Mu, Chun Li, Xiaomei Li, Yao Ke, Ling Zhao, Lin Chen, Rui Wu, Zhenbiao Wu, Xiaoxia Zuo, Yanli Xie, Jinwei Chen, Wei Wei, Yi Liu, Zhijun Li, Lie Dai, Lingyun Sun, Xiangyuan Liu & Zhanguo Li. (2021) Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. The Lancet Regional Health - Western Pacific 10, pages 100128.
Crossref
Chang-hong Li, Zhen-zhen Ma, Lei-lei Jian, Xin-yu Wang, Lin Sun, Xiang-yuan Liu, Zhong-qiang Yao & Jin-xia Zhao. (2021) Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways. International Immunopharmacology 90, pages 107219.
Crossref
Yuening Kang, Qingran Yan, Qiong Fu, Ran Wang, Min Dai, Fang Du, Qing Dai, Ping Ye, Chunmei Wu, Liangjing Lu & Chunde Bao. (2020) Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study. Arthritis Research & Therapy 22:1.
Crossref
Asuka Inoue, Yuji Nozaki, Yasuaki Hirooka, Koji Kinoshita, Yasutaka Chiba, Masanori Funauchi & Itaru Matsumura. (2020) The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care. Life 10:11, pages 261.
Crossref
Bingtong Li, Ping Li & Liqi Bi. (2019) Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients. Clinical Rheumatology 39:3, pages 899-907.
Crossref
Sisi Xie, Shu Li, Jing Tian & Fen Li. (2020) Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape. Frontiers in Pharmacology 11.
Crossref
Huihui Jiang, Hongyan Gao, Qin Wang, Miao Wang & Bin Wu. (2020) Molecular mechanisms and clinical application of Iguratimod: A review. Biomedicine & Pharmacotherapy 122, pages 109704.
Crossref
Eijiro Jimi, Nana Takakura, Fumitaka Hiura, Ichiro Nakamura & Shizu Hirata-Tsuchiya. (2019) The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition “Killing Two Birds with One Stone”?. Cells 8:12, pages 1636.
Crossref
Yan Ye, Mei Liu, Longhai Tang, Fang Du, Yuanhua Liu, Pei Hao, Qiong Fu, Qiang Guo, Qingran Yan, Xiaoming Zhang & Chunde Bao. (2019) Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. Arthritis Research & Therapy 21:1.
Crossref
François Vercruysse, Thomas Barnetche, Estibaliz Lazaro, Emilie Shipley, François Lifermann, Alexandre Balageas, Xavier Delbrel, Bruno Fautrel, Christophe Richez, Thierry Schaeverbeke & Marie-Elise Truchetet. (2019) Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Research & Therapy 21:1.
Crossref
Jie Li, Jun Bao, Jian Zeng, Aizhu Yan, Chunqiu Zhao & Qiang Shu. (2019) Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology. Bone Research 7:1.
Crossref
. (2019) Iguratimod/warfarin. Reactions Weekly 1748:1, pages 246-246.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.